FISONS' OPTICROM INSPECTION SCHEDULED FOR WEEK OF APRIL 20,
FISONS' OPTICROM INSPECTION SCHEDULED FOR WEEK OF APRIL 20, the British pharmaceutical firm said April 3. FDA will inspect Fisons' revamped Holmes Chapel, U,.K manufacturing facility for the anti-allergy eye drops. Opticrom (cromolyn sodium) was withdrawn from the U.S. market in July 1990; if FDA clears Fison's upgraded facility, the company will reintroduce the product into the U.S. Fisons earlier had projected a first quarter inspection for both Opticrom and its injectable iron product Imferon, which was withdrawn from the U.S. market in May 1991 ("The Pink Sheet" Jan. 20, T&G-12). Imferon, however, will not be included in the upcoming FDA inspection, Fisons said. "After a full technical review" of Imferon, Fisons said it "has been decided that the FDA should not be asked to audit the Imferon process during their inspection." The company is "currently reviewing the options available...in terms of future [Imferon] supply and will come forward with conclusions and associated action plan as soon as the review is completed." On April 2, Fisons announced a further shift in executive positions with the appointment of Cedric Scroggs as CEO and pharmaceutical division chairman. Scroggs has served as scientific equipment division chairman since 1981. He takes over the CEO duties from John Kerridge, who resigned as chairman and CEO on Jan. 14, and the pharmaceutical division top post from Peter Fothergill, who also has resigned, Fisons said. In announcing the appointment, new Fisons' Chairman Patrick Egan said that Scroggs will be joining a pharmaceutical operation that has been "strengthened by the recruitment" of a number of outside managers. These include Managing Director-Marketing Operations Mike Redmond, who joined from Schering-Plough last year; Director of Technical Operations Bill Clark, who joined from Searle; European Regional Director Brian Tempest, a Glaxo veteran who joined in February; and Director of Quality Assurance David Pendergast, who came on board in March from Upjohn. The outcome of the FDA Opticrom inspection could have a major impact on Fisons' financial fortunes. When the problems uncovered by a 1991 FDA inspection of the Holmes Chapel facility emerged, the company had predicted that "profitability will...return to normality in the second half of the year" from resupply of both Opticrom and Imferon ("The Pink Sheet" Jan. 6, p. 17).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth